Rifapentine

Rifapentine

File:Rifapentine.png
Clinical data
ATC code	J04AB05 (WHO)
Pharmacokinetic data
Bioavailability	increases when administered with food
Identifiers
IUPAC name 3{[(4-cyclopentyl-1-piperazinyl)imino]methyl}rifamycin
CAS Number	61379-65-5
PubChem CID	5462354
DrugBank	APRD01217
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C47H64N4O12
Molar mass	877.031 g/mol

WikiDoc Resources for Rifapentine
Articles
Most recent articles on Rifapentine Most cited articles on Rifapentine Review articles on Rifapentine Articles on Rifapentine in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Rifapentine Images of Rifapentine Photos of Rifapentine Podcasts & MP3s on Rifapentine Videos on Rifapentine
Evidence Based Medicine
Cochrane Collaboration on Rifapentine Bandolier on Rifapentine TRIP on Rifapentine
Clinical Trials
Ongoing Trials on Rifapentine at Clinical Trials.gov Trial results on Rifapentine Clinical Trials on Rifapentine at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Rifapentine NICE Guidance on Rifapentine NHS PRODIGY Guidance FDA on Rifapentine CDC on Rifapentine
Books
Books on Rifapentine
News
Rifapentine in the news Be alerted to news on Rifapentine News trends on Rifapentine
Commentary
Blogs on Rifapentine
Definitions
Definitions of Rifapentine
Patient Resources / Community
Patient resources on Rifapentine Discussion groups on Rifapentine Patient Handouts on Rifapentine Directions to Hospitals Treating Rifapentine Risk calculators and risk factors for Rifapentine
Healthcare Provider Resources
Symptoms of Rifapentine Causes & Risk Factors for Rifapentine Diagnostic studies for Rifapentine Treatment of Rifapentine
Continuing Medical Education (CME)
CME Programs on Rifapentine
International
Rifapentine en Espanol Rifapentine en Francais
Business
Rifapentine in the Marketplace Patents on Rifapentine
Experimental / Informatics
List of terms related to Rifapentine

Rifapentine (marketed under the brand name Priftin by Aventis) is an antibiotic drug used in the treatment of tuberculosis.

History

Rifapentin was first synthesized in 1965 by the same company that produced rifampin. The drug was approved by the Food and Drug Administration (FDA) in June 1998.

External links

• Rosenthal IM, Zhang M, Williams KN, Peloquin CA, Tyagi S, et al. 2007. Daily Dosing of Rifapentine Cures Tuberculosis in Three Months or Less in the Murine Model. PLoS Medicine Vol. 4, No. 12, e344 doi:10.1371/journal.pmed.0040344 [1]

Template:WH Template:WS